FDA New Drug Application In The Works For This Innovator In ADHD Drug Delivery from john lundgren retired ceo from stanley Watch Video
Preview(s): Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Your browser does not support playing the video.Please download the video!
⏲ Duration: 12:6 👁 View: 2.2M times ✓ Published: 10-May-2024
Description: Shane Schaffer, Chairman & CEO, and Peter J. Werth, Board Member of Cingulate, were recently guests on Benzinga's All Access.<br/><br/>Cingulate is a biotechnology company that is developing drugs for a range of underserved conditions. The company has developed a proprietary technology called Precision Timed Release™ (PTR™). The technology allows a single pill to contain multiple doses of a drug, allowing for relief of the pill burden many people with chronic conditions suffer.<br/><br/>The company is preparing an application for new drug approval for its lead candidate, CTx-1301.